Home › GLP-1 Medications › Eli Lilly
Latest three-month snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.
GLP-1 Medications · 1 wave · n=72 answers, pooled
How often each model brings the brand up in recommendation answers.
| model | share of voice | answers |
|---|---|---|
| ChatGPT | 96% | 23 of 24 |
| Claude | 100% | 24 of 24 |
| Gemini | 67% | 16 of 24 |
Wave-by-wave share of recommendation answers that named this brand.
| wave | share of voice | answers | change |
|---|---|---|---|
| 2026-08-05 | 88% | 63 of 72 |
Recurring descriptions in the models' own words, grouped by theme.
“If you are looking to lose weight, **Zepbound (tirzepatide)** is the superior choice by a wide margin.”
“They are administered as a weekly injection, have the same side effects, and come in the exact same doses (ranging from 2.”
“Rybelsus is a daily oral tablet, whereas Mounjaro is a once-weekly subcutaneous injection.”
“* **Your primary goals are maximum weight loss and superior blood sugar control:** Mounjaro is a dual-action medication (targeting both GIP and GLP-1 receptors), making it highly effective.”
“* **FDA Approval:** Zepbound is specifically FDA-approved for chronic weight management (for adults with obesity, or those who are overweight with at least one weight-related condition).”
“If you **do not** have Type 2 diabetes, insurance will almost certainly deny coverage for Mounjaro. You will have to pay the full out-of-pocket retail price (often upwards of $1,000/month).”
“Because they are FDA-approved for entirely different medical conditions, choosing the wrong one could mean your insurance won't cover it or you won't get the specific health benefits you need.”
“medications like Wegovy (semaglutide) and Zepbound (tirzepatide) are also expensive brand-name drugs, they are weekly injections (rather than daily, like Saxenda) and are clinically shown to produce greater weight loss. If you have commercial insurance, manufacturers offer saving”
“If you do not have Type 2 diabetes and your goal is chronic weight management, **Zepbound** is the correct choice.”
“If you are eligible for either and the deciding goal is **the greatest average weight loss**, choose Zepbound (tirzepatide).”
589 exact quoted mentions in this snapshot, grouped by coded tone. Recent quotes are deduplicated and mixed across models.
“**Zepbound** — assuming your goal is weight loss or long-term weight management.”
“A weekly injection that targets both GLP-1 and GIP receptors, showing very high efficacy for blood sugar control and weight loss”
“Zepbound (tirzepatide): This is Wegovy's main competitor. It is a "dual-agonist" (targeting both GLP-1 and GIP receptors) and has shown slightly higher average weight loss in clinical trials (around 20%”
“For most eligible adults seeking the greatest average weight loss, ask a clinician about _Zepbound_ (tirzepatide) first. It is a once-weekly GIP/GLP-1 medicine approved for long-term weight management, and is also approved for moderate-to-s”
“**Zepbound** (tirzepatide) – weekly injection, dual GLP-1/GIP agonist”
“Mounjaro (tirzepatide) is among the most effective non-insulin medicines for **type 2 diabetes**, particularly when lowering A1C *and* losing weight are priorities.”
“Ask your plan specifically which of these is preferred: **generic liraglutide, Ozempic, Mounjaro, Trulicity, or Victoza-equivalent generic.**”
“brand-name Mounjaro ($1,023–$1,060/month) without insurance”
“GLP-1 medications (like Ozempic, Wegovy, Mounjaro, and Zepbound)”
“It's a GLP-1 receptor agonist that helps lower A1C levels effectively”
“Do not buy Ozempic or Mounjaro "for weight loss" on your own; they are branded for diabetes, while **Wegovy and Zepbound** are the FDA-approved brands specifically for chronic weight management.”
“Avoid compounded "semaglutide" or "tirzepatide," research peptides, and products claiming to be generic Ozempic/Wegovy/Mounjaro/Zepbound.”
“Generic exenatide is available at a lower cost, though the twice-daily dosing makes Byetta less convenient than once-weekly options. It also lacks the proven cardiovascular benefits seen with newer GLP-1 drugs and doesn't produce weight los”
“Novo Nordisk is currently suing Eli Lilly over Zepbound ads. The ads compare Lilly's Zepbound with Novo's Wegovy, and Novo argues they give consumers a misleading picture of how the drugs compare”
“Brand-name weekly GLP-1s (like Ozempic, Wegovy, or Mounjaro) do not have generic options yet and routinely cost upwards of $900 to $1,000+ per month without insurance.”
Which competitors models suggest when shoppers ask for something cheaper.
89 of 590 mentions appear alongside an identifiable web citation. Citation does not establish causation.
| cited source | mentions |
|---|---|
| noom.com | 8 |
| goodrx.com | 8 |
| formblends.com | 7 |
| drugs.com | 6 |
| injectco.com | 6 |
| singlecare.com | 6 |
| doctronic.ai | 5 |
| fda.gov | 5 |
| pandameds.com | 5 |
| sesamecare.com | 5 |
| preventionclinics.com | 4 |
| weightwatchers.com | 4 |
Stores and sites models name as places to buy this brand.
| retailer | mentions |
|---|---|
| LillyDirect | 35 |
| Costco | 3 |
| Kroger | 1 |
| Walmart | 1 |
| GoodRx | 1 |
| SingleCare | 1 |
| participating pharmacies | 1 |
| Sesame | 1 |
Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.